Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRA NASDAQ:ATYR NASDAQ:LFCR NASDAQ:MRSN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$11.94-1.5%$11.46$5.01▼$18.70$85.12M0.2249,604 shs31,487 shsATYRaTyr Pharma$1.01-83.3%$5.28$1.00▼$7.29$590.86M1.014.70 million shs153.80 million shsLFCRLifecore Biomedical$7.68+2.1%$7.54$4.33▼$8.85$281.31M0.64121,186 shs105,763 shsMRSNMersana Therapeutics$7.17+0.4%$7.55$5.21▼$70.75$35.63M0.8666,734 shs30,072 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics-1.49%-1.97%-2.85%+53.08%+22.84%ATYRaTyr Pharma-83.25%-81.50%-79.39%-80.35%-46.84%LFCRLifecore Biomedical+2.13%+5.35%+4.21%+12.78%+48.26%MRSNMersana Therapeutics+0.42%+1.85%+0.14%-18.85%-86.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$11.94-1.5%$11.46$5.01▼$18.70$85.12M0.2249,604 shs31,487 shsATYRaTyr Pharma$1.01-83.3%$5.28$1.00▼$7.29$590.86M1.014.70 million shs153.80 million shsLFCRLifecore Biomedical$7.68+2.1%$7.54$4.33▼$8.85$281.31M0.64121,186 shs105,763 shsMRSNMersana Therapeutics$7.17+0.4%$7.55$5.21▼$70.75$35.63M0.8666,734 shs30,072 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics-1.49%-1.97%-2.85%+53.08%+22.84%ATYRaTyr Pharma-83.25%-81.50%-79.39%-80.35%-46.84%LFCRLifecore Biomedical+2.13%+5.35%+4.21%+12.78%+48.26%MRSNMersana Therapeutics+0.42%+1.85%+0.14%-18.85%-86.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.80Moderate Buy$21.0075.88% UpsideATYRaTyr Pharma 2.50Moderate Buy$23.252,201.98% UpsideLFCRLifecore Biomedical 2.50Moderate Buy$8.004.17% UpsideMRSNMersana Therapeutics 3.00Buy$56.60689.40% UpsideCurrent Analyst Ratings BreakdownLatest ATRA, LFCR, ATYR, and MRSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025ATYRaTyr PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight9/15/2025ATYRaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral9/15/2025ATYRaTyr PharmaLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform9/15/2025ATYRaTyr PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral9/3/2025LFCRLifecore BiomedicalKeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSector Weight8/22/2025ATYRaTyr PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $17.008/14/2025MRSNMersana TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$250.00 ➝ $36.008/14/2025MRSNMersana TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$125.00 ➝ $30.008/13/2025MRSNMersana TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.006/20/2025ATYRaTyr PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$17.00 ➝ $25.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$128.94M0.65N/AN/A($16.89) per share-0.71ATYRaTyr Pharma$230K430.30N/AN/A$0.83 per share1.22LFCRLifecore Biomedical$128.87M2.23N/AN/A$0.04 per share192.00MRSNMersana Therapeutics$40.50M0.88N/AN/A($1.92) per share-3.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$85.40M-$0.43N/AN/AN/A3.07%-8.34%6.61%11/11/2025 (Estimated)ATYRaTyr Pharma-$64.02M-$0.80N/AN/AN/AN/A-93.69%-68.83%11/6/2025 (Estimated)LFCRLifecore Biomedical-$38.72M-$1.31N/AN/AN/A-31.70%-846.51%-13.03%10/3/2025 (Estimated)MRSNMersana Therapeutics-$69.19M-$14.62N/AN/AN/A-212.94%-990.16%-54.85%11/12/2025 (Estimated)Latest ATRA, LFCR, ATYR, and MRSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/3/2025Q1 2026LFCRLifecore Biomedical-$0.29N/AN/AN/A$26.68 millionN/A8/13/2025Q2 2025MRSNMersana Therapeutics-$3.75-$4.08-$0.33-$4.87$6.06 million$3.06 million8/11/2025Q2 2025ATRAAtara Biotherapeutics-$0.32$0.19+$0.51$0.19$4.23 million$17.58 million8/7/2025Q2 2025ATYRaTyr Pharma-$0.18-$0.22-$0.04-$0.22N/AN/A8/7/2025Q4 2025LFCRLifecore Biomedical-$0.09-$0.10-$0.01-$0.06$35.36 million$36.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AATYRaTyr PharmaN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A1.701.70ATYRaTyr Pharma0.015.635.63LFCRLifecore Biomedical113.762.841.77MRSNMersana TherapeuticsN/A1.351.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%ATYRaTyr Pharma61.72%LFCRLifecore Biomedical83.36%MRSNMersana Therapeutics93.92%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.00%ATYRaTyr Pharma3.70%LFCRLifecore Biomedical32.20%MRSNMersana Therapeutics13.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3307.02 million6.74 millionOptionableATYRaTyr Pharma5397.99 million94.36 millionOptionableLFCRLifecore Biomedical69037.41 million25.36 millionOptionableMRSNMersana Therapeutics1504.99 million4.34 millionOptionableATRA, LFCR, ATYR, and MRSN HeadlinesRecent News About These CompaniesMartin Jr. Huber Sells 2,012 Shares of Mersana Therapeutics (NASDAQ:MRSN) Stock2 hours ago | insidertrades.comMersana Therapeutics (NASDAQ:MRSN) Shares Up 0.4% - Here's Why4 hours ago | americanbankingnews.comWall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?September 8, 2025 | zacks.comMersana Therapeutics Faces Nasdaq Non-Compliance NoticeSeptember 6, 2025 | msn.comWall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a BetAugust 22, 2025 | zacks.comMersana Therapeutics price target adjusted to $36 at Truist after reverse splitAugust 14, 2025 | msn.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | insidermonkey.comMersana Therapeutics Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comMersana Therapeutics reports Q2 EPS ($4.87), consensus ($4.25)August 13, 2025 | msn.comMersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial ResultsAugust 13, 2025 | finanznachrichten.deMersana Misses Fiscal Q2 Revenue TargetAugust 13, 2025 | theglobeandmail.comMersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial ResultsAugust 13, 2025 | finance.yahoo.comMersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue EstimatesAugust 13, 2025 | zacks.comMersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial ResultsAugust 13, 2025 | globenewswire.comMersana Therapeutics Q2 2025 Earnings PreviewAugust 12, 2025 | msn.comA Look at Mersana Therapeutics's Upcoming Earnings ReportAugust 12, 2025 | benzinga.comEarnings To Watch: Mersana Therapeutics Inc (MRSN) Reports Q2 2025 ResultAugust 12, 2025 | finance.yahoo.comMersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025August 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATRA, LFCR, ATYR, and MRSN Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$11.94 -0.18 (-1.49%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$11.88 -0.06 (-0.54%) As of 09/15/2025 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.aTyr Pharma NASDAQ:ATYR$1.01 -5.02 (-83.25%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.10 +0.09 (+8.51%) As of 06:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Lifecore Biomedical NASDAQ:LFCR$7.68 +0.16 (+2.13%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$7.69 +0.01 (+0.12%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Mersana Therapeutics NASDAQ:MRSN$7.17 +0.03 (+0.42%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$7.30 +0.13 (+1.81%) As of 05:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
